US · NVST · MEDICAL - INSTRUMENTS & SUPPLIES
Envista Holdings Corp (NVST) intrinsic value and stock valuation
$22.91as of 2026-11-21 · Mkt cap 4.66B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Envista Holdings Corp DCF and intrinsic value
InvestorsCraft values NVST with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from NVST’s statements →
Envista Holdings Corp Graham Number
Graham Number: $10.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.72B | $2.51B | $2.57B | $2.57B | $2.51B |
| Operating income | $225.7M | -$-1.04B | $31.5M | $319.2M | $306.2M |
| Net income | $47M | -$-1.12B | -$-100.2M | $243.1M | $340.5M |
| EPSd | $277.8K | -$-6.5M | -$-600.36K | $1.37M | $1.92M |
| Operating cash flow | $275.7M | $336.5M | $275.7M | $182.7M | $361.6M |
| Capital expenditure | -$-45.3M | -$-33.8M | -$-58.2M | -$-75.7M | -$-54.7M |
| Free cash flow | $230.4M | $302.7M | $217.5M | $107M | $306.9M |
| Total assets | $5.68B | $5.35B | $6.61B | $6.59B | $6.57B |
| Total debt | $1.6B | $1.55B | $1.65B | $1.53B | $1.48B |
| Net debt | $386M | $478.6M | $713.6M | $922.2M | $410M |
| Total equity | $3.11B | $2.93B | $4.17B | $4.21B | $4.06B |
| Cash and short-term investments | $1.21B | $1.07B | $940M | $606.9M | $1.07B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.72B | $2.51B | $2.57B | $2.57B | $2.51B |
| Cost of revenue | $1.22B | $1.12B | $1.12B | $1.08B | $1.05B |
| Gross profit | $1.5B | $1.39B | $1.45B | $1.49B | $1.46B |
| Research and development expenses | $114M | $99.1M | $93.8M | $100.1M | $100.5M |
| Selling, general and administrative expenses | $1.16B | $1.14B | $1.03B | $1.03B | $989.5M |
| Other expenses | $0.00 | $1.19B | $295.9M | $40.7M | $66.2M |
| Operating expenses | $1.27B | $2.43B | $1.42B | $1.17B | $1.16B |
| Cost and expenses | $2.49B | $3.55B | $2.54B | $2.25B | $2.2B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $36.6M | $46.4M | $63.4M | $38.4M | $54.1M |
| Depreciation and amortization | $116M | $123.1M | $135.6M | $137.8M | $123.6M |
| Ebitda | $329.8M | $279.5M | $463M | $497.7M | $496M |
| Operating income | $225.7M | -$-1.04B | $31.5M | $319.2M | $306.2M |
| Total other income/expenses, net | -$-48.5M | -$-46.5M | -$-86.4M | -$-35.3M | -$-51.7M |
| Income before tax | $177.2M | -$-1.08B | -$-54.9M | $283.9M | $254.5M |
| Income tax expense | $130.2M | $33.9M | $45.3M | $45.9M | -$-9M |
| Net income | $47M | -$-1.12B | -$-100.2M | $243.1M | $340.5M |
| Weighted average shares outstanding | $168M | $172.2M | $166.9M | $162.9M | $161.2M |
| Weighted average diluted shares outstanding | $169.2M | $172.2M | $166.9M | $177.6M | $177.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.21B | $1.07B | $940M | $606.9M | $1.07B |
| Net receivables | $429.6M | $363M | $407.5M | $393.5M | $331.9M |
| Inventory | $288.1M | $241M | $258.8M | $300.8M | $263.8M |
| Total current assets | $2.03B | $1.79B | $1.74B | $1.42B | $1.84B |
| Property, plant and equipment, net | $438.9M | $419.8M | $434.7M | $425.4M | $392.2M |
| Goodwill and intangible assets | $2.99B | $2.91B | $4.25B | $4.58B | $4.18B |
| Long-term investments | $0.00 | $26.4M | $0.00 | $0.00 | -$-160.5M |
| Total non-current assets | $3.65B | $3.56B | $4.86B | $5.16B | $4.74B |
| Total assets | $5.68B | $5.35B | $6.61B | $6.59B | $6.57B |
| Accounts payable | $191.6M | $174.6M | $179.5M | $228.3M | $185.8M |
| Short-term debt | $39M | $150.5M | $145.6M | $537M | $479.8M |
| Deferred revenue | $184.8M | $146.5M | $106.4M | $78.9M | $60.1M |
| Total current liabilities | $852.6M | $878.7M | $780.8M | $1.24B | $1.21B |
| Long-term debt | $1.56B | $1.4B | $1.51B | $992.1M | $1B |
| Deferred revenue, non-current | $22.4M | $20.3M | $8.4M | $8.6M | $5.1M |
| Total non-current liabilities | $1.72B | $1.54B | $1.65B | $1.14B | $1.31B |
| Capital lease obligations | $149.4M | $153.4M | $140.2M | $148.4M | $144.1M |
| Total liabilities | $2.57B | $2.42B | $2.43B | $2.38B | $2.52B |
| Common stock | $1.8M | $1.7M | $1.7M | $1.6M | $1.6M |
| Retained earnings | -$-440.4M | -$-487.4M | $631.2M | $731.4M | $466.9M |
| Accumulated other comprehensive income (loss) | -$-113.2M | -$-371.1M | -$-217.2M | -$-225.1M | -$-143.5M |
| Total equity | $3.11B | $2.93B | $4.17B | $4.21B | $4.06B |
| Total investments | $0.00 | $26.4M | $0.00 | $0.00 | -$-160.5M |
| Total debt | $1.6B | $1.55B | $1.65B | $1.53B | $1.48B |
| Net debt | $386M | $478.6M | $713.6M | $922.2M | $410M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $47M | -$-1.12B | -$-100.2M | $243.1M | $340.5M |
| Depreciation and amortization | $150.7M | $154.5M | $162.6M | $162.1M | $151.9M |
| Stock-based compensation | $37.6M | $35.3M | $30.7M | $30.5M | $28.2M |
| Change in working capital | $8.9M | $97.4M | -$-108.4M | -$-271.7M | -$-203.2M |
| Accounts receivable | -$-48.5M | $10M | -$-17M | -$-71M | -$-43.2M |
| Inventory | -$-29.1M | $3.6M | $35.1M | -$-39.9M | -$-66M |
| Accounts payable | $7.5M | -$-1.2M | -$-46.3M | $44.5M | -$-20.3M |
| Net cash provided by operating activities | $275.7M | $336.5M | $275.7M | $182.7M | $361.6M |
| Investments in property, plant and equipment | -$-45.3M | -$-33.8M | -$-58.2M | -$-75.7M | -$-54.7M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-622.3M | $310.4M |
| Net cash used for investing activities | -$-51.1M | -$-54.6M | -$-62.4M | -$-657.3M | $262.7M |
| Common stock issued | $2.8M | $2.4M | $11.3M | $21.8M | $19.5M |
| Common stock repurchased | -$-166.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-170.9M | -$-103.7M | $118.9M | $12.5M | -$-465.6M |
| Net change in cash | $142.6M | $129.1M | $333.1M | -$-466.7M | $184.7M |
| Cash at end of period | $1.21B | $1.07B | $940M | $606.9M | $1.07B |
| Operating cash flow | $275.7M | $336.5M | $275.7M | $182.7M | $361.6M |
| Capital expenditure | -$-45.3M | -$-33.8M | -$-58.2M | -$-75.7M | -$-54.7M |
| Free cash flow | $230.4M | $302.7M | $217.5M | $107M | $306.9M |
Line items
Line items
Line items
About Envista Holdings Corp
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
- CEO
- Paul A. Keel
- Employees
- 12K
- Beta
- 0.86
Explore
Frequently asked questions
What is the intrinsic value of Envista Holdings Corp (NVST)?
Envista Holdings Corp (NVST) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NVST undervalued?
NVST trades at a price of $22.91 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.